AbbVie Inc. (NYSE: ABBV)
Health Care · Biotechnology · US
$276.47
+1.49% today · +19.8% 1Y
AbbVie Inc. (NYSE: ABBV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $488.55B and employs 57,000 people.
Over the last twelve months the share price has gained 19.8%, trading between 190.75 and 274.94.
Tweenvest scores AbbVie Inc. across four factors: quality 72/100, value 16/100, growth 33/100, dividend 86/100. Its strongest factor is dividend.
ABBV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $488.55B
- Revenue (TTM)
- $64.39B
- P/E
- 78.11
- EPS
- 3.54
- Dividend yield
- 2.54%
- Beta (5Y)
- 0.23
- 52-week high
- $274.94
- 52-week low
- $190.75
- Avg volume (3M)
- —
- Shares outstanding
- 1.77B
- Employees
- 57,000
- Next earnings
- —
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- ISIN
- US00287Y1091
- Founded
- 2012
- Listed since
- Jan 2, 2013
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Amgen Inc.NasdaqGS: AMGN | $224.29B | $414.87 | +1.82% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $187.44B | $151.17 | +2.77% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $129.29B | $510.08 | +1.36% |
| Moderna, Inc.NasdaqGS: MRNA | $89.83B | $225.00 | +14.21% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $74.55B | $746.54 | +0.94% |
| CSL LimitedASX: CSL | $61.44B | AU$183.84 | +1.31% |
| Natera, Inc.NasdaqGS: NTRA | $57.76B | $400.71 | +2.54% |
| argenx SEENXTBR: ARGX | $51.01B | €728.40 | +3.23% |
Figures last refreshed Oct 11, 2026.